Research programme: mTORC1 modulators - Navitor Pharmaceuticals

Drug Profile

Research programme: mTORC1 modulators - Navitor Pharmaceuticals

Latest Information Update: 26 Apr 2015

Price : $50

At a glance

  • Originator Navitor Pharmaceuticals; X-Chem
  • Developer Navitor Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action MTORC1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Metabolic disorders; Musculoskeletal disorders; Neurodegenerative disorders

Most Recent Events

  • 31 Mar 2015 Small-molecule mTORC1 modulators licensed to Navitor pharmaceuticals worldwide
  • 19 Jun 2014 Early research in Neurodegenerative disorders in USA (unspecified route)
  • 19 Jun 2014 Early research in Musculoskeletal disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top